PubMed Daily Triage Digest — 2026-07-27
Run ID: 2026-07-27-attempt2-20260727T091948Z
Status: PARTIAL_SUCCESS (metadata-only scoring; efetch abstracts not retrieved)
Window: 2026-07-26 00:00 UTC → 2026-07-27 23:59 UTC (CRDT)
Articles: 29 total | HIGH: 12 | STANDARD: 17
Topics scanned: 10 (9 watchlist + 1 sentinel)
🔴 HIGH Priority (Score ≥ 8 or NOVEL_TREATMENT / EARLY_CANCER_DETECTION flag)
Score 9
PMID 42503467 🟠 NOVEL_TREATMENT
Phase 1 clinical trial of S64315, an intravenous MCL1 inhibitor, in patients with myeloid malignancies.
Vey N et al. Leukemia & Lymphoma 2026-07-26
Topics: Hematologic malignancies | Evidence: Exploratory
First-in-human clinical data for S64315 (MIK665), a first-in-class IV MCL1 inhibitor. Phase 1 trial in AML/MDS — a long-validated but previously undruggable apoptosis target. Authors include Daver N, Wei AH (leading hematology centers).
PMID 42503495 🟠 NOVEL_TREATMENT
Efficacy of CagriSema for Reaching Anthropometric Treatment Targets and Cardiometabolic Outcomes: A Secondary, Post hoc Analysis of REDEFINE 1.
Busetto L et al. (le Roux CW last). Diabetes Obesity & Metabolism 2026-07-26
Topics: Cardiovascular-metabolic | Evidence: Potentially Practice-Changing
CagriSema (cagrilintide + semaglutide) Phase 3 secondary analysis characterizing cardiometabolic outcomes beyond weight loss. Next-generation GLP-1+amylin combination now with REDEFINE 1 efficacy data.
PMID 42503568 🟢 NEAR_TERM_IMPLEMENTABLE
Nonadherence to GLP-1 Receptor Agonists Among Individuals With Overweight or Obesity: A Systematic Review and Meta-Analysis of RCTs.
Shegena EA et al. Obesity Reviews 2026-07-26
Topics: Cardiovascular-metabolic | Evidence: Validated
First meta-analysis quantifying GLP-1 RA nonadherence rates from RCT data. Direct clinical utility for optimizing real-world GLP-1 RA prescribing strategies.
PMID 42502668 🟢 NEAR_TERM_IMPLEMENTABLE
Randomized Controlled Trial of Large Language Model-Assisted Diagnostic Accuracy in Nephrology.
Bentegeac R et al. Kidney International Reports 2026-06-23 [PMC13400205]
Topics: AI/ML diagnostics | Evidence: Potentially Practice-Changing
First RCT of LLM-assisted clinical diagnosis in any medical specialty. Provides direct human-outcome evidence for clinical AI deployment. PMC full text available.
PMID 42503527 🟢 NEAR_TERM_IMPLEMENTABLE
The deep learning radiomics nomogram for risk stratification in multiple myeloma using automatic whole-body [18F]FDG PET/CT segmentation.
Xiao M et al. (Zhang H last). Eur J Nucl Med Mol Imaging 2026-07-27
Topics: Hematologic malignancies, AI/ML diagnostics | Evidence: Validated
Validated DL radiomics nomogram for non-invasive MM risk stratification using automated whole-body PET/CT segmentation. Cross-topic T1+T4.
Score 8
PMID 42502985 🟢 NEAR_TERM_IMPLEMENTABLE
EGFR-mutant NSCLC progressing on first-line osimertinib: rebiopsy in real-world and impact of second-line therapies ('Rebiopsy on osi' Study).
Gariazzo E et al. (Metro G last; ~50 authors). The Oncologist 2026-07-25
Topics: Precision oncology, Novel therapeutics | Evidence: Validated
Large Italian multicenter (50 centers) real-world rebiopsy dataset at osimertinib progression. Directly actionable data on resistance mechanisms and second-line therapy outcomes.
PMID 42502690 🟢 NEAR_TERM_IMPLEMENTABLE
Identifying and characterizing the germinal genetic landscape of men with prostate cancer: A real-life, retrospective, multicenter study.
Svirsky R et al. Genetics in Medicine Open 2026-07-26 [PMC13400249]
Topics: Precision oncology | Evidence: Validated
8-center Israeli real-world germline profiling of prostate cancer patients. Actionable BRCA1/2/ATM variant prevalence for PARP inhibitor eligibility guidance. PMC open.
PMID 42502998 🟢 NEAR_TERM_IMPLEMENTABLE
Risk stratification, treatment patterns and survival outcomes in newly diagnosed multiple myeloma: Chinese Myeloma Committee real-world database study.
Chinese Myeloma Committee. British Journal of Haematology 2026-07-26
Topics: Hematologic malignancies | Evidence: Validated
Largest Chinese real-world NDMM database study establishing survival benchmarks and identifying treatment pattern gaps in Asian populations.
PMID 42502197 🔴 EARLY_CANCER_DETECTION
Detection of Point Mutation in Individual Living Circulating Malignant Cells by Targeting Molecular Beacon Delivery.
Liao XR et al. Small 2026-07-25
Topics: Early cancer detection | Evidence: Exploratory
Single-cell point mutation detection in living CTCs using targeted molecular beacons. Proof-of-concept for ultra-precise liquid biopsy.
Score 5 — Elevated by NOVEL_TREATMENT flag
PMID 42502508 🟠 NOVEL_TREATMENT [score capped: non-human]
Pharmacokinetic and pharmacodynamic characterization of CD8-targeted lentiviral vector for in vivo CD19-directed CAR-T therapy.
Duback V et al. Molecular Therapy Advances 2026-07-03 [PMC13400396]
Topics: Novel therapeutics | Evidence: Exploratory
CD8-targeted LV enables in vivo CAR-T generation without ex vivo manufacturing — paradigm-shifting if translatable. Score capped at 5 (mouse model). PMC open.
PMID 42503607 🟠 NOVEL_TREATMENT [score capped: non-human]
Introducing Borsantrazole: A Trifunctional Boron-Based Pyrazole That Extends the Lifespan of Amyotrophic Lateral Sclerosis Mice.
Sanghai N et al. Advanced Science 2026-07-26
Topics: Rare diseases (ALS) | Evidence: Exploratory
Novel boron-based trifunctional compound extends ALS mouse lifespan. New chemical scaffold for a disease with extreme unmet need. Published in Advanced Science (IF ~14).
PMID 42503304 🔴 EARLY_CANCER_DETECTION [score 7 → HIGH by flag]
Extracellular Vesicles in Cancer: Biomarkers, Mechanisms, and Emerging Diagnostic Technologies.
Wang C et al. Advanced Healthcare Materials 2026-07-26
Topics: Early cancer detection, Precision oncology | Evidence: Exploratory
Comprehensive review of EV-based cancer biomarkers and emerging liquid biopsy diagnostic platforms. Covers clinical translation pipeline for EV diagnostics.
🟡 STANDARD Highlights by Topic (Score 5–7)
T1 — Hematologic Malignancies
- 42503233 (7) ML model for high-risk infection prediction in cancer patients — Cancer Medicine
- 42503043 (6) CSF1R in myeloid cells has limited impact on CLL — Br J Haematol (informative negative result for TME targeting)
- 42503308 (6) FL grades 1-2 cytomorphological differentiation using ImageJ — Diagnostic Cytopathology
T5 — Precision Oncology
- 42503372 (6) GPNMB as pharmacological target in cancer: ADC development — Biochemical Pharmacology
T6 — Novel Therapeutics
- 42503051 (7) HCC treatment landscape 10-year real-world evolution including immunotherapy era — Targeted Oncology
- 42503385 (6) EV-mediated immunity-coagulation in cancer thrombosis during immunotherapy — Crit Rev Oncol Hematol
- 42503264 (6) PLOD2 promotes CRC immune escape via CD8+ T cell suppression — Int Immunopharmacol
- 42503059 (6) Adjuvant ICI in resected NSCLC with non-EGFR/ALK drivers — Clin Transl Oncol
T7 — Cardiovascular-Metabolic
- 42503575 (7) Cost-effectiveness model: semaglutide 2.4 mg vs resmetirom 80/100 mg vs SoC for MASH — PharmacoEconomics
- 42503500 (6) EDGEFIRM Trial design: TEER vs GDMT in atrial functional MR + HFpEF — ESC Heart Fail
- 42503388 (5) LV dimension as independent factor for NT-proBNP values in heart failure — Am J Med
T8 — Aging, Longevity, Population Health
- 42503507 (7) IDEAL-Age: interpretable DL framework for single-cell immunological aging profiling — Genome Biology (OA)
- 42503573 (7) Sex differences in dementia pathology in ethnically diverse Brazilian autopsy study — Alzheimer's & Dementia
- 42502879 (6) Inflammaging: experimental insights and translational advances (expert review by Cossarizza A) — Eur J Immunol
T9 — Rare Diseases
- 42502545 (5) Early psychiatric manifestations of Lafora disease (case report, exception rule) — Cureus [PMC open]
T6 — Preclinical (score capped at 5, PROMISING_PRELIMINARY)
- 42503514 (5) Chenodeoxycholic acid/TGR5/cDC1 cross-priming tumor suppression — Signal Transduct Target Ther
- 42503515 (5) Bacteria-mimicking cancer cells reprogram macrophages for immunotherapy — Signal Transduct Target Ther
Coverage Notes
| Topic | Results | Reviewed | HIGH | STANDARD | Notes |
|---|---|---|---|---|---|
| T1 Hematologic malignancies | 27 | 14/15 | 3 | 5 | 42503072 excluded (esummary not confirmed); 3 false positives |
| T2 CBC/ML hematology | 1 | 1 | 0 | 0 | Only 1 result; MDS case series, low T2 relevance |
| T3 Early cancer detection | 4 | 4 | 2 | 0 | 2 false positives |
| T4 AI/ML diagnostics | 3 | 3 | 1 | 0 | 42503527 captured in T1, cross-listed |
| T5 Precision oncology | 6 | 6 | 3 | 2 | 1 plant biology false positive |
| T6 Novel therapeutics | 17 | 15 | 2 | 8 | Non-human cap applied to 4 articles |
| T7 Cardiovascular-metabolic | 39 | 15 | 2 | 5 | 1 false positive (air pollution/puberty) |
| T8 Aging/longevity | 17 | 15 | 0 | 5 | 8 Russian Adv Gerontol papers scored LOW |
| T9 Rare diseases | 4 | 4 | 1 | 1 | Case report exception rule applied (Lafora) |
| Sentinel | 198 | 10 | 2 | 3 | 5 sentinel PMIDs not confirmed via esummary |
Protocol deviations this run:
- efetch (abstract retrieval) NOT run; all scoring from title + esummary metadata only → classification_confidence set to medium/low throughout
- Attempt 2 of 3 (attempt 1 failed with timeout/provider error)
- Missing: PMID 42503072 (T1) and 5 sentinel PMIDs not fully confirmed